Lewati ke konten

Informasi medis independen untuk pasien internasional

Menu

Penyakit

Breast cancer

ICD-10: C50 — Malignant neoplasm of breast

Kelompok: Kanker Spesialisasi: Bedah Payudara

Angka utama

Hanya nilai yang diterbitkan. Setiap ubin membuka bagian yang memuat sumber, tahun, dan kalibernya.

Rincian penyakit

Nama Inggris
Malignant neoplasm of breast

Juga dikenal sebagai

  • Breast carcinoma

Kisaran biaya pengobatan

Setiap kisaran di bawah diterbitkan pada satu dasar penagihan: Sebelum penggantian asuransi. Sumber tidak menerbitkan angka setelah penggantian, jadi tidak ada yang ditampilkan di sini.

Jalur pengobatan Kisaran biaya Dasar harga Tahun data
Pembedahan 18000 – 28430 CNY Harga paket per penyakit 2020–2025
Radioterapi 27000 – 45000 CNY Harga per item 2025–2026
Kemoterapi 6200 – 9000 CNY Harga paket per penyakit 2020–2021
Terapi bertarget 100000 – 195000 CNY Harga per item 2025
Imunoterapi 32043 – 42620 CNY Harga per item 2024–2025

Batang-batang berbagi satu skala di seluruh baris di atas: masing-masing dimulai dari angka terbit terendah baris itu dan berakhir pada angka tertingginya. Angka tertinggi di halaman ini adalah 195000 CNY. Setiap baris mempertahankan tahun data dan kalibernya sendiri.

5 kisaran biaya untuk penyakit ini, dengan sumbernya di halaman baris.

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Lihat semua kisaran biaya →

Kelangsungan hidup lima tahun

Tingkat kelangsungan hidup 5 tahun 80.9% IK 95% 80.5–81.3

Populasi
Keseluruhan (semua stadium digabung) · Tingkat kelangsungan hidup relatif terstandar usia
Periode
2019–2021
Penerbit
Pusat Kanker Nasional Tiongkok
Sifat nilai
Nilai estimasi (analisis campuran)
Cakupan registri
281 registri kanker berbasis populasi
Ketersediaan data stadium
Tidak diterbitkan

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Lihat semua tingkat kelangsungan hidup →

Cara membaca angka ini. Angka ini diterbitkan untuk semua stadium digabung, jadi ini rata-rata atas semua orang dalam data registri nasional, bukan prognosis untuk satu orang. Pada sebagian besar kanker, stadium saat diagnosis adalah faktor tunggal terkuat di balik perbedaan kelangsungan hidup: kelangsungan hidup umumnya lebih tinggi bila kanker ditemukan pada stadium lebih dini dan lebih rendah bila ditemukan lebih lambat. Perbandingan antar kanker juga dipengaruhi oleh seberapa dini atau lambat masing-masing cenderung didiagnosis, jadi angka yang lebih rendah tidak dengan sendirinya berarti mutu layanan yang lebih buruk.

Angka itu adalah kelangsungan hidup relatif: angka ini membandingkan orang yang didiagnosis kanker ini dengan orang seusia dan sejenis kelamin dalam populasi umum, dan distandardisasi menurut umur, jadi bukan proporsi pasien yang masih hidup setelah lima tahun. Angka ini diterbitkan sebagai nilai perkiraan (analisis hibrida) karena laporan registri datang dengan jeda, sehingga National Cancer Center memodelkan periode terakhir. Sebagai konteks, sumber yang sama menerbitkan kelangsungan hidup relatif lima tahun 43,7% untuk semua kanker gabungan pada 2019–2021.

Rumah sakit dengan catatan terbit untuk penyakit ini

Dipilih menggunakan sumber data publik resmi

Rumah sakit ini dipilih dari sumber data publik resmi — peringkat reputasi spesialisasi rumah sakit Universitas Fudan, daftar spesialisasi klinis kunci nasional, dan pusat riset klinis nasional — sehingga setiap baris pada kartu dapat diperiksa terhadap sumber terbitnya. Ini bukan daftar berbayar atau promosi.

Bagaimana rumah sakit ini dipilih

Penerimaan. Sebuah rumah sakit dicantumkan untuk suatu penyakit bila spesialisasi tempat penyakit itu dikelompokkan memuat paling sedikit satu dari: posisi atau nominasi dalam peringkat reputasi spesialisasi rumah sakit Universitas Fudan; catatan spesialisasi klinis kunci nasional pada tingkat A, B, atau C; atau pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu. Akreditasi JCI ditampilkan sebagai lencana; akreditasi itu tidak pernah menentukan penerimaan dan tidak pernah menentukan urutan.

Urutan. Langkah 1: posisi Fudan antara 1 dan 10 untuk spesialisasi itu. Langkah 2: posisi Fudan lain, atau nominasi. Langkah 3: spesialisasi klinis kunci nasional tingkat A. Langkah 4: spesialisasi klinis kunci nasional tingkat B. Langkah 5: pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu, pusat sebelum laboratorium. Langkah 6: spesialisasi klinis kunci nasional tingkat C, yaitu catatan yang kami terbitkan tanpa sumber resmi independen sehingga dicantumkan setelah yang lain.

Seri. Dalam satu langkah: posisi Fudan yang lebih baik lebih dahulu, lalu tingkat spesialisasi kunci yang lebih kuat (A sebelum B sebelum C), lalu provinsi, lalu kota, lalu nama rumah sakit - urutan provinsi-kota-nama yang sama seperti yang dipakai direktori rumah sakit. Paling banyak delapan rumah sakit dicantumkan.

Bila daftar pendek. Lima rumah sakit atau lebih: delapan yang pertama dicantumkan. Tiga atau empat: semuanya dicantumkan, dan satu lipatan tambahan menambahkan catatan sisanya sampai delapan, masing-masing membawa tingkat buktinya. Satu atau dua: sama, dengan lipatan itu terbuka dan satu baris yang menyatakan berapa rumah sakit yang memiliki catatan publik kuat. Tidak ada: halaman menyatakan bahwa tidak ditemukan catatan publik kuat dan menautkan ke direktori spesialisasi. Posisi, lembaga, atau jumlah tidak pernah diciptakan untuk mengisi daftar.

Peringkat Fudan adalah peringkat reputasi spesialisasi rumah sakit yang paling luas diakui oleh dokter Tiongkok, diterbitkan setiap tahun oleh institut manajemen rumah sakit Universitas Fudan.

  1. West China Hospital, Sichuan University

    Chengdu

    Spesialisasi klinis kunci nasional

    Juga diperingkat: Bedah Umum #3, Bedah Toraks #4, Urologi #2 (seri) dalam daftar Fudan.

  2. Qilu Hospital of Shandong University

    Jinan

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    3 studi terbit lainnya

    PubMed mengindeks 5 makalah tentang penyakit ini yang menyebut rumah sakit ini.

    Juga diperingkat: Ginekologi #7 (seri), Otolaringologi dinominasikan, Gastroenterologi dinominasikan dalam daftar Fudan.

  3. Shandong Cancer Hospital

    Jinan

    Spesialisasi klinis kunci nasional

  4. Hubei Cancer Hospital

    Wuhan

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    3 studi terbit lainnya

    PubMed mengindeks 5 makalah tentang penyakit ini yang menyebut rumah sakit ini.

  5. Hunan Cancer Hospital

    Changsha

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    PubMed mengindeks 1 makalah tentang penyakit ini yang menyebut rumah sakit ini.

    Juga diperingkat: Onkologi Medis dinominasikan dalam daftar Fudan.

Uji klinis (pengobatan dalam penelitian)

Selain perawatan standar, studi riset klinis untuk Breast cancer mungkin sedang terbuka bagi peserta di Tiongkok. Pengobatan yang diteliti belum disetujui regulator sebagai terapi standar — itu riset klinis, bukan perawatan rutin. Setiap catatan menyebutkan peneliti utama dan rumah sakit yang menjalankan studi itu. Bila Anda berminat, hubungi rumah sakit untuk menanyakan kelayakan dan tentukan sendiri apakah ingin mendaftar.

  1. Studi To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients: A Prospective, Multicenter, Non-interventionist Real World Study

    Rumah sakit
    Henan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06605521

  2. Studi Integrated PET/MRI Study of Cognitive Impairment in Premenopausal Breast Cancer Patients After Chemotherapy or Endocrine Therapy

    Status
    Sedang merekrut
    Registri
    NCT05305092

  3. Studi The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery: an Observational Cohort Study

    Peneliti utama
    Chen Kai · Clinical Professor
    Rumah sakit
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Sedang merekrut
    Registri
    NCT06425874

  4. Studi Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

    Rumah sakit
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Sedang merekrut
    Registri
    NCT07372079

  5. Studi Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer

    Rumah sakit
    The Affiliated Hospital of Qingdao University
    Status
    Sedang merekrut
    Registri
    NCT06916338
126 studi terdaftar lainnya

  1. Studi Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Stage II-III HER2-positive Breast Cancer Patients Who Have Poor Outcomes After Treatment With Trastuzumab and Pertuzumab

    Peneliti utama
    Caigang Liu · Director
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT04983121

  2. Studi Effect of Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer Without Lymph Node Metastasis Instead of Conventional Imaging Examination After Operation: a Non-Inferiority Randomized Controlled Clinical Trial

    Peneliti utama
    Jianyi Li · Principal Investigator
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT04065321

  3. Studi A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

    Peneliti utama
    Caigang Liu · Director of the Cancer Center
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT05635487

  4. Studi VERITAS Longitudinal Real-world Registry of HR+/HER2- mBC to Understand Treatment Pattern and Clinical Outcomes in HR+/HER2- mBC

    Rumah sakit
    Jiangsu Province Hospital
    Status
    Sedang merekrut
    Registri
    NCT07743944

  5. Studi A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.

    Rumah sakit
    Anhui Provincial Hospital
    Status
    Sedang merekrut
    Registri
    NCT05872347

  6. Studi Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in All-Scenario Breast Cancer Radiotherapy: A Prospective Clinical Study

    Peneliti utama
    Xiaoli Yu · Professor
    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT07776301

  7. Studi A Cohort Study of Adjuvant Therapy With Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

    Peneliti utama
    Shu Wang · director of breast center
    Rumah sakit
    Peking University People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06711055

  8. Studi Neoadjuvant Therapy Study Guided by Drug Screening in Vitro Patient-derived Tumor-like Cell Clusters for HER2 Positive Early Breast Cancer Patients

    Rumah sakit
    Peking University People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT04750122

  9. Studi Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial

    Status
    Sedang merekrut
    Registri
    NCT06938360

  10. Studi A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    Peneliti utama
    Shuangyue Liu · Clinical Professor
    Rumah sakit
    West China Hospital, Sichuan University
    Status
    Sedang merekrut
    Registri
    NCT05447702

  11. Studi Application of Radiomics in Correlation Between Ultrasound Characteristics and Pathological Prognostic Factors in Breast Cancer

    Rumah sakit
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT04483804

  12. Studi Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

    Rumah sakit
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT07616440

  13. Studi Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05): A Prospective, Single-arm, Multi-center Clinical Study

    Rumah sakit
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT06832904

  14. Studi Safety and Feasibility of Irreversible Electroporation for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study

    Peneliti utama
    Tian'an Jiang · Chief Physician
    Rumah sakit
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT07263451

  15. Studi Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) for Chronic Insomnia in Breast Cancer Survivors, A Randomized Controlled Trial

    Peneliti utama
    Jing MA · Pro.
    Rumah sakit
    Peking University First Hospital
    Status
    Sedang merekrut
    Registri
    NCT05813392

  16. Studi Impact of Erector Spinae Plane Block With Adjuvant Dexmedetomidine on Chronic Postsurgical Pain in Breast Cancer Patients: a Two-center Randomized Controlled Trial

    Peneliti utama
    Dong-Xin Wang · Professor
    Rumah sakit
    Peking University First Hospital
    Status
    Sedang merekrut
    Registri
    NCT05494502

  17. Studi A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT05851014

  18. Studi A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07673029

  19. Studi A Real-World Observational Study on Post-Resistance Treatment Outcomes in Advanced Breast Cancer Patients After CDK4/6 Inhibitors, PIK3CA Inhibitors, or Trastuzumab Deruxtecan Therapy

    Rumah sakit
    Hunan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07073755

  20. Studi A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6is.

    Rumah sakit
    Hunan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06734533

  21. Studi A Prospective, Multigroup, Multi-center, Open-label Clinical Study of Trastuzumab Rezetecan as Neoadjuvant Therapy Combined With Toripalimab in HR+/HER2-low Breast Cancer Patients (NEOTORCH-BREAST 08)

    Rumah sakit
    Third Affiliated Hospital of Harbin Medical University
    Status
    Sedang merekrut
    Registri
    NCT07383818

  22. Studi A Randomized, Multi-center, Open-label, Phase III Trial of Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer (FAMILY)

    Peneliti utama
    Herui Yao · Principal Investigator
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT04263298

  23. Studi A Randomized, Open-label, Multicenter Study Comparing Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

    Rumah sakit
    Fujian Medical University Union Hospital
    Status
    Sedang merekrut
    Registri
    NCT05292742

  24. Studi Trastuzumab Combined With Pyrotinib and Chemotherapy for Locally Advanced, Inflammatory, or Early HER2-positive Mammary glandsCancer: One Arm, Open, Phase II Clinical Study

    Peneliti utama
    Tao OUYANG · Chairman of Breast Center of Peking University Cancer Hospital
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT04481932

  25. Studi Intraoperative Nomogram to Predict Breast Cancer- Related Lymphedema Based in Artificial Intelligence Image Recognition: a Randomized Controlled Trial

    Peneliti utama
    Gaosong Wu, Ph D, MD · Director
    Rumah sakit
    Zhongnan Hospital of Wuhan University
    Status
    Sedang merekrut
    Registri
    NCT04665882

  26. Studi A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06120283

  27. Studi A Randomized Controlled, Open-label, Multicenter Clinical Study of Pyrotinib Maleate Combined With Trastuzumab,Dalpiciclib, and Letrozole Versus Trastuzumab Combined With Pertuzumab, Docetaxel, and Carboplatin as Neoadjuvant Therapy for Stage II-III HR +/HER2 + Breast Cancer

    Peneliti utama
    Caigang Liu · Professor
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT05638594

  28. Studi Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer

    Peneliti utama
    Jianyi Li · Principal Investigator
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT05346510

  29. Studi A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer

    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT06178159

  30. Studi Effect of Neoadjuvant Radiation and Prediction of Response to Treatment in Locally Advanced Breast Cancer

    Peneliti utama
    Xiaoli Yu · Professor
    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT05479409

  31. Studi A Cohort Study of Different Choice of Adjuvant Therapy in Non-PCR Patients With HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

    Peneliti utama
    Shu Wang · director of breast center
    Rumah sakit
    Peking University People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06693037

  32. Studi A Single-center, Single-arm, Open Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

    Status
    Sedang merekrut
    Registri
    NCT07071402

  33. Studi Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer

    Status
    Sedang merekrut
    Registri
    NCT07012720

  34. Studi A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

    Rumah sakit
    Beijing Hospital
    Status
    Sedang merekrut
    Registri
    NCT05950945

  35. Studi Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression

    Rumah sakit
    Xiangya Hospital of Central South University
    Status
    Sedang merekrut
    Registri
    NCT06938373

  36. Studi A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribulin Versus Physician's Choice Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

    Peneliti utama
    Jieqiong Liu, M.D., Ph.D. · Professor
    Rumah sakit
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Sedang merekrut
    Registri
    NCT06889688

  37. Studi Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer (TAYLOR-003)

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07616427

  38. Studi A Randomized, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in Patients With HER2-positive Advanced Breast Cancer

    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT07008976

  39. Studi Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer

    Status
    Sedang merekrut
    Registri
    NCT04353557

  40. Studi A Prospective, Randomized Controlled Phase II Trial Investigating the Optimal Timing of Antibody Drug Conjugates in Advanced HER2-Negative Breast Cancer Patients

    Peneliti utama
    Tao Sun · Principal Investigator
    Rumah sakit
    Liaoning Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07657130

  41. Studi A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Therapy for Luminal-type Breast Cancer

    Peneliti utama
    HAN GUANG · professor
    Rumah sakit
    Hubei Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06402435

  42. Studi A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

    Peneliti utama
    HAN GUANG · professor
    Rumah sakit
    Hubei Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06401005

  43. Studi Gut Microbiota Changes in Breast Cancer Patients Treated With Pyrotinib and Correlation With Drug-Induced Diarrhea: An Observational Cohort Study

    Peneliti utama
    Xinhong Wu, PhD · vice-president
    Rumah sakit
    Hubei Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT07264985

  44. Studi Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold for Left Sided Breast Cancer, A Real-World Study

    Rumah sakit
    Peking Union Medical College Hospital
    Status
    Sedang merekrut
    Registri
    NCT06660628

  45. Studi Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

    Rumah sakit
    Peking Union Medical College Hospital
    Status
    Sedang merekrut
    Registri
    NCT06411678

  46. Studi A Single-center, Blinded, Efficacious, Phase III Randomized Clinical Trial Initiated by Investigators to Investigate the Use of Surface Guided Radiation Therapy (SGRT) in Combination With Deep Inspiration Breath Hold (DIBH) Technique for Left Breast Cancer Treatment, Compared to Traditional Laser Alignment With Free Breathing Treatment

    Rumah sakit
    Peking Union Medical College Hospital
    Status
    Sedang merekrut
    Registri
    NCT05804916

  47. Studi Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study

    Peneliti utama
    Zhimin Shao · Professor
    Rumah sakit
    The First Affiliated Hospital of Anhui Medical University
    Status
    Sedang merekrut
    Registri
    NCT04790305

  48. Studi Surveillance of Circulating Tumor Cell Phenotype in Early Stage Breast Cancer Patients With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy

    Rumah sakit
    Hunan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT05326295

  49. Studi A Single-arm, Multicenter, Open-labeled Clinical Study of UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

    Rumah sakit
    Hunan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT05535413

  50. Studi A Clinical Study of Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR Positive HER2 Positive Breast Cancer

    Rumah sakit
    Henan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06276868

  51. Studi Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer: a Prospective, Multicenter, Single Arm, Real World Study

    Rumah sakit
    Henan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06518135

  52. Studi A Single-arm, Prospective, Open-label Phase II Clinical Study of Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

    Rumah sakit
    Henan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT05398861

  53. Studi Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

    Peneliti utama
    Zhenzhen Liu · Professor
    Rumah sakit
    Henan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06860529

  54. Studi Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With HER2 Negative Metastatic Breast Cancer Treated With Sacituzumab Govitecan: A Retrospective Trial in China（SACIT-OUT）

    Peneliti utama
    Wang Xiaojia · MD
    Rumah sakit
    Zhejiang Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06784921

  55. Studi A Phase II, Randomised, Open-label, Multicentre Study of Posaconazole Plus PD-1 Inhibitors and Chemotherapy Versus PD-1 Inhibitors and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer

    Peneliti utama
    Yongsheng Wang · Professor
    Rumah sakit
    Shandong Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06802757

  56. Studi Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

    Rumah sakit
    Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT06977893

  57. Studi A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

    Rumah sakit
    China-Japan Friendship Hospital
    Status
    Sedang merekrut
    Registri
    NCT06210776

  58. Studi Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating

    Peneliti utama
    Yong Yang · Chief physician
    Rumah sakit
    Fujian Medical University Union Hospital
    Status
    Sedang merekrut
    Registri
    NCT05704166

  59. Studi Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy: a Phase III Randomized, Controlled Clinical Trial

    Peneliti utama
    Yong Yang · M.D.
    Rumah sakit
    Fujian Medical University Union Hospital
    Status
    Sedang merekrut
    Registri
    NCT06559696

  60. Studi A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Evaluating TQB2930 Combined With Investigator's Choice of Chemotherapy Versus Trastuzumab Combined With Investigator's Choice of Chemotherapy in the Treatment of HER2-Positive Advanced Breast Cancer

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07047365

  61. Studi Efficacy and Safety of Probiotics Versus Standard Care in Preventing Diarrhea Induced by Neratinib in Breast Cancer Patients: A Prospective Randomized Controlled Clinical Trial

    Rumah sakit
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Sedang merekrut
    Registri
    NCT06892093

  62. Studi Disitamab Vedotin in Combination With Pyrotinib Versus THP in the First-line Treatment for HER2-positive Advanced Breast Cancer, a Multicentre, Randomized, Double-blind Controlled, Phase III Trial

    Rumah sakit
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Sedang merekrut
    Registri
    NCT06278870

  63. Studi Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

    Rumah sakit
    The Affiliated Hospital of Qingdao University
    Status
    Sedang merekrut
    Registri
    NCT06916637

  64. Studi A Non-interventional Study to Evaluate the Effectiveness and Safety of Inavolisib in Patients With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (reaINAVO)

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07347600

  65. Studi An Interventional, Multicenter Study of Trastuzumab Rezetecan as Neoadjuvant Therapy in Patients With THP-Insensitive HER2-Positive Early Breast Cancer

    Peneliti utama
    Hao Zhou · Associate Chief Physician
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07647263

  66. Studi Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial

    Peneliti utama
    Caigang Liu · Principal Investigator
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT04137653

  67. Studi The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer

    Peneliti utama
    Caigang Liu · Director of oncology
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT06690645

  68. Studi The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.

    Peneliti utama
    Caigang Liu · Professor
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT05263570

  69. Studi Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial

    Peneliti utama
    Caigang Liu · Principal Investigator
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT04136782

  70. Studi The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer

    Peneliti utama
    Caigang Liu · director of oncology
    Rumah sakit
    Shengjing Hospital
    Status
    Sedang merekrut
    Registri
    NCT06698679

  71. Studi A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06827236

  72. Studi A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection in Patients With Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER-2) Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT07498478

  73. Studi Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial

    Peneliti utama
    Zhong-yu Yuan · Clinical Professor
    Rumah sakit
    Sun Yat-sen University Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT04722978

  74. Studi A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer: A Prospective Randomized Controlled Trial

    Peneliti utama
    Kun Wang · Clinical Professor
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT07352930

  75. Studi A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients

    Peneliti utama
    Kun Wang · Professor
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06811870

  76. Studi Clinical Cohort Study of 21-gene Assay in Predicting the Prognosis of Elder Luminal-A Breast Cancer Patients With Axillary Lymph Node Metastasis

    Rumah sakit
    Qilu Hospital of Shandong University
    Status
    Sedang merekrut
    Registri
    NCT06891651

  77. Studi Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined With TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer

    Peneliti utama
    Jian Zhang,MD · Director of Phase I clinical Research ward
    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT06793332

  78. Studi Evaluating Safety and Efficacy of INtrathecal or Ommaya ReserVoir Administration of T-DXd in Patients With HER2-Expressing Breast Cancer With Active Leptomeningeal and/or Brain Metastases Based on Systemic Therapy: Phase I/II Study

    Peneliti utama
    Jian Zhang,MD · Director of Phase I Clinical Trial Department; Professor, Chief physician of oncology department
    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT07134153

  79. Studi A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

    Peneliti utama
    Zhimin Shao · Chief Physician
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT05891093

  80. Studi Cohort Study of Adjuvant Chemotherapy Combined With Targeted Therapy for Intermediate Risk HER2 Positive and Lymph Node Negative Early Breast Cancer

    Peneliti utama
    Shu Wang · director of breast center
    Rumah sakit
    Peking University People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06711068

  81. Studi A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy

    Rumah sakit
    Cancer Hospital of Chinese Academy of Medical Sciences
    Status
    Sedang merekrut
    Registri
    NCT07679360

  82. Studi IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

    Rumah sakit
    Anhui Provincial Hospital
    Status
    Sedang merekrut
    Registri
    NCT06926868

  83. Studi A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT06891833

  84. Studi A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07043725

  85. Studi The Safety and Efficacy of IMPT or IMRT for Breast Cancer: A Prospective Observational Study

    Peneliti utama
    JIAYI CHEN · Chair of Radiation Oncology Department
    Rumah sakit
    Ruijin Hospital
    Status
    Sedang merekrut
    Registri
    NCT06826885

  86. Studi Prospective Randomized Controlled Study on Precision Irradiation of Regional Lymph Node for Clinical High-risk pN0 Breast Cancer

    Peneliti utama
    JIAYI CHEN · Prof
    Rumah sakit
    Ruijin Hospital
    Status
    Sedang merekrut
    Registri
    NCT05976412

  87. Studi Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy: a Prospective, Multicenter, Clinical Trial

    Peneliti utama
    Chunyan Ma · Chief of Cardiovascular Ultrasound
    Rumah sakit
    First Hospital of China Medical University
    Status
    Sedang merekrut
    Registri
    NCT06282796

  88. Studi A Phase 2 Trial of SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

    Peneliti utama
    Min Yan, MD · Chief physician
    Rumah sakit
    Henan Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07125950

  89. Studi Sensitivity and Specificity of Ultrasound-Guided Core Needle Biopsy in Evaluating Axillary Lymph Node Metastasis in Breast Cancer

    Peneliti utama
    Dezhi Zhang · Principal Investigator (PI)
    Rumah sakit
    The First Hospital of Jilin University
    Status
    Belum merekrut
    Registri
    NCT07573657

  90. Studi A Multicenter, Randomized, Controlled, Open Label Clinical Study on the Treatment of Recurrent or Metastatic Triple Negative Breast Cancer With Cadonilimab Combined With Eribulin Versus Eribulin Alone

    Peneliti utama
    Caigang Liu · Postdoctoral, Chief Physician
    Rumah sakit
    Shengjing Hospital
    Status
    Belum merekrut
    Registri
    NCT06202313

  91. Studi An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

    Peneliti utama
    Caigang Liu · Shengjing Hospital
    Rumah sakit
    Shengjing Hospital
    Status
    Belum merekrut
    Registri
    NCT07101614

  92. Studi A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients

    Peneliti utama
    Kun Wang · PhD
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT06825975

  93. Studi A Phase 2, Single Arm Study Investigating the Use of Chidamide and PD-1 Antibody Combination With Anlotinib in HER2-low, Unresectable and/or Metastatic Breast Cancer

    Peneliti utama
    Kun Wang · Professor
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT06547476

  94. Studi Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer After Trastuzumab Deruxtecan Resistance:A Single-Arm, Multicenter, Exploratory Clinical Study

    Status
    Belum merekrut
    Registri
    NCT07333937

  95. Studi Tolerability of Dalpiciclib Versus Abemaciclib/Ribociclib in Combination With Standard Endocrine Therapy for HR-Positive/HER2-Negative Early Breast Cancer: A Prospective, Multicenter, Randomized Controlled Trial

    Peneliti utama
    Zhenzhen Liu · Professor
    Rumah sakit
    Henan Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07706933

  96. Studi A Multicenter, Prospective, Randomized Two-arm Controlled Trial Comparing the Impact of Robotic Versus Endoscopic Surgery on Breast Nerve Function Following Nipple-sparing Mastectomy for Breast Cancer

    Peneliti utama
    haiyanli · Chief Physician, Department of Breast Surgery
    Rumah sakit
    Guangzhou Women and Children's Medical Center
    Status
    Belum merekrut
    Registri
    NCT07850154

  97. Studi Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

    Rumah sakit
    The First Hospital of Jilin University
    Status
    Belum merekrut
    Registri
    NCT06868017

  98. Studi Efficacy and Safety of SHR-A1811 Versus Pyrotinib Plus Capecitabine in Patients With Trastuzumab Primary-Resistant HER2-Positive Advanced Breast Cancer：A Prospective, Multicenter, Open-Label, Randomized, Controlled Study

    Peneliti utama
    Hanfang Jiang, MD · Professor
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07417241

  99. Studi A Clinical Model Based on Dynamic Changes in Anti-Müllerian Hormone to Predict Ovarian Reserve in Perimenopausal Breast Cancer Patients

    Peneliti utama
    Jianyi Li · Chief Physician
    Rumah sakit
    Shengjing Hospital
    Status
    Belum merekrut
    Registri
    NCT07497191

  100. Studi Trastuzumab Combined With Pertuzumab and Sequential Use of Pyrotinib vs. Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

    Peneliti utama
    Caigang Liu · Director
    Rumah sakit
    Shengjing Hospital
    Status
    Belum merekrut
    Registri
    NCT04973319

  101. Studi Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer

    Peneliti utama
    Kun Wang · Professor
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT07077018

  102. Studi A Prospective Study to Evaluate the Clinical Significance of Medical Humanities-based Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage

    Peneliti utama
    Jiong Wu · Principal Investigator
    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Belum merekrut
    Registri
    NCT06965556

  103. Studi 针刺治疗激素受体阳性乳腺癌患者潮热的随机对照试验研究，A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer

    Peneliti utama
    Shu Wang · director of breast center
    Rumah sakit
    Peking University People's Hospital
    Status
    Belum merekrut
    Registri
    NCT07294339

  104. Studi A Multicenter, Single-Arm, Open-Label Study of Extended Sentinel Lymph Node Biopsy Using Methylene Blue as a Single Tracer After Neoadjuvant Therapy in Patients With Axillary Node-Positive Breast Cancer

    Status
    Belum merekrut
    Registri
    NCT07532096

  105. Studi SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases

    Rumah sakit
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Belum merekrut
    Registri
    NCT06975475

  106. Studi Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression: A Randomized Controlled Trial

    Peneliti utama
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Rumah sakit
    Chinese PLA General Hospital
    Status
    Belum merekrut
    Registri
    NCT07374198

  107. Studi Effects of Acupuncture for Anxiety and/or Depression Among Patients With Breast Cancer

    Peneliti utama
    Yuanjie Sun · Attending physician
    Rumah sakit
    Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Status
    Belum merekrut
    Registri
    NCT07183813

  108. Studi Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer: A Historical Cohort Study

    Rumah sakit
    Zhejiang Hospital
    Status
    Belum merekrut
    Registri
    NCT07188116

  109. Studi A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

    Peneliti utama
    Xuli Meng · Chief physician
    Rumah sakit
    Zhejiang Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT06975644

  110. Studi A Phase Ib, Open-label, Modular Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

    Rumah sakit
    Hunan Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07163481

  111. Studi The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

    Peneliti utama
    Wang Xiaojia · chief physician
    Rumah sakit
    Zhejiang Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT06140576

  112. Studi A Prospective and Multicenter Clinical Study to Identify the Molecular Characterization and Subtypes in Patients With HER2-positive Breast Cancer Receiving Neoadjuvant Trastuzumab and Pertuzumab.

    Peneliti utama
    Jinming Yu · PhD, MD
    Rumah sakit
    Shandong Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07187752

  113. Studi Efficacy and Safety of Pedicled Lateral Chest Wall Lymph-Adipofascial Flap Axillary Reconstruction for the Prevention of Breast Cancer-Related Arm Lymphedema: A Prospective, Single-Arm, Phase II Clinical Study

    Rumah sakit
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Belum merekrut
    Registri
    NCT07415200

  114. Studi A Multicenter, Prospective Phase II Single-arm Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with T-DXd in Combination with an Immune Checkpoint Inhibitor in HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

    Peneliti utama
    Huijin Wang · Director of Thyroid and Breast Disease Center
    Rumah sakit
    Guangzhou Women and Children's Medical Center
    Status
    Belum merekrut
    Registri
    NCT06733233

  115. Studi Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer

    Rumah sakit
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Belum merekrut
    Registri
    NCT07697443

  116. Studi A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases, With or Without Leptomeningeal Metastases.

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07177950

  117. Studi A Prospective, Double-Arm Study on the Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

    Peneliti utama
    xuliang · professor
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07527806

  118. Studi Prospective Evaluation of Sentinel Lymph Node Biopsy Combined With Wire Localized Lymph Node Biopsy for Omitting Axillary Lymph Node Dissection in Breast Cancer Patients With 1-2 Sonographically Abnormal Lymph Nodes: A Diagnostic Study

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07791771

  119. Studi Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Breast Cancer

    Rumah sakit
    The Affiliated Hospital of Qingdao University
    Status
    Belum merekrut
    Registri
    NCT05505812

  120. Studi A Single-Center Retrospective Study to Develop a Nomogram for Predicting Recurrence in HR+/HER2- Early Breast Cancer Using Real-World Data

    Peneliti utama
    Jianyi Li · Principal Investigator
    Rumah sakit
    Shengjing Hospital
    Status
    Belum merekrut
    Registri
    NCT07484763

  121. Studi An Exploration of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery

    Peneliti utama
    Kun Wang · Professor
    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT06811857

  122. Studi A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study of Paclitaxel Polymeric Micelles Combined With Trastuzumab and Pertuzumab (HP) and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer

    Peneliti utama
    Jian Zhang,MD · Director of Phase I Unit，Chief physician of oncology department
    Rumah sakit
    Fudan University Shanghai Cancer Center
    Status
    Belum merekrut
    Registri
    NCT07581795

  123. Studi A Multicenter, Prospective, Randomized Phase II Trial Evaluating Trastuzumab, Pertuzumab, Docetaxel Combined With QL1706 Versus Combined With Carboplatin as Neoadjuvant Therapy for Early or Locally Advanced HER2+ Breast Cancer

    Rumah sakit
    Guangdong Provincial People's Hospital
    Status
    Belum merekrut
    Registri
    NCT07246317

  124. Studi Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

    Peneliti utama
    Yingying Xu · Professor
    Rumah sakit
    First Hospital of China Medical University
    Status
    Belum merekrut
    Registri
    NCT07305246

  125. Studi TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

    Peneliti utama
    Yingying Xu · Professor
    Rumah sakit
    First Hospital of China Medical University
    Status
    Belum merekrut
    Registri
    NCT07271992

  126. Studi Effect of Intraoperative Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery: A Multicenter, Randomized, Double-Blind, Sham-Controlled Trial

    Peneliti utama
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Rumah sakit
    Beijing Tiantan Hospital, Capital Medical University
    Status
    Belum merekrut
    Registri
    NCT07458646

Halaman ini hanya membagikan informasi studi yang terdaftar secara publik. Halaman ini tidak menganjurkan atau mendorong keikutsertaan dalam studi mana pun. Keikutsertaan sepenuhnya sukarela dan risiko pengobatan yang belum disetujui tidak diketahui; hubungi rumah sakit langsung untuk kelayakan dan rincian persetujuan setelah penjelasan.

Terapi lanjutan: apa yang sudah berizin dan apa yang masih dalam uji klinis

Rumah sakit dengan catatan spesialisasi kunci nasional

Tampilkan catatan rumah sakit 5 rumah sakit dengan catatan spesialisasi kunci

Setiap baris adalah rumah sakit dengan catatan spesialisasi klinis kunci nasional pada spesialisasi tempat penyakit ini dikelompokkan. Ini catatan daftar terbit, bukan rekomendasi dan bukan peringkat.

Rumah sakit Kota Spesialisasi (sebagaimana diterbitkan) Bukti Sumber
West China Hospital, Sichuan University
Tier 3 · TERTINGGI
 Chengdu Bedah Payudara Tingkat A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Qilu Hospital of Shandong University
Tier 3 · TERTINGGI
 Jinan Bedah Payudara Tingkat A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Shandong Cancer Hospital Jinan Bedah Payudara Tingkat A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Hubei Cancer Hospital Wuhan Bedah Payudara Tingkat B https://www.hbch.com.cn/category/1-11.html
Hunan Cancer Hospital
Tier 3 · TERTINGGI
 Changsha Bedah Payudara Tingkat B https://hnca.org.cn/wap/zdks/

5 rumah sakit dengan catatan spesialisasi kunci nasional yang cocok.

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Apa yang dilaporkan pasien

Hanya angka agregat: hasil nasional yang dikutip dengan sumbernya dan tahun yang dirujuknya. Ini bukan testimoni pasien dan bukan pernyataan tentang satu orang.

  • Sebagaimana dilaporkan dalam National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.

    National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).

    Sumber: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Tingkat A

Semua topik terapi & akses

Pertanyaan tentang penyakit ini

Kami tidak dapat memberikan nasihat medis, tetapi kami dapat menjawab pertanyaan tentang halaman ini dan tentang mengatur pengobatan di Tiongkok.

Tanyakan kepada kami tentang kondisi ini

Kode ICD

Tampilkan tabel kode 10 kode ICD
Versi Kode Nama dalam versi itu
ICD-10-WHO C50 Malignant neoplasm of breast
ICD-10-WHO C50.0 Nipple and areola
ICD-10-WHO C50.1 Central portion of breast
ICD-10-WHO C50.2 Upper-inner quadrant of breast
ICD-10-WHO C50.3 Lower-inner quadrant of breast
ICD-10-WHO C50.4 Upper-outer quadrant of breast
ICD-10-WHO C50.5 Lower-outer quadrant of breast
ICD-10-WHO C50.6 Axillary tail of breast
ICD-10-WHO C50.8 Overlapping lesion of breast
ICD-10-WHO C50.9 Breast, unspecified

Baris-barisnya adalah entri ICD-10 WHO untuk penyakit ini, dikutip sebagaimana diterbitkan.

Sumber & bukti

URL sumber
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Skema sumber
https
Jenis sumber
Komisi kesehatan provinsi
Tingkat bukti
A - dinyatakan oleh komisi kesehatan, lembaga riset nasional, atau universitas
Diambil pada
2026-09-24